Protara Therapeutics, Inc. - Common Stock (TARA) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
53/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$4.12
Trend Context
Mixed / range
Latest briefing
What's happening with TARA
businesswire.com15 Jun 2026
Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today announced the launch of TARA (Tradeweb AI Research Assistant), a conversational AI-powered assistant designed to help institutional U.S. credit market participants transform trading data into actionable real-time market intelligence and trading insights. Embedded directly within the Tradeweb institutional platform, TARA enables users to query trading activity, market.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com20 May 2026
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of t…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com19 May 2026
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
18 May 2026
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
